US20160166570A1 - Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin - Google Patents

Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin Download PDF

Info

Publication number
US20160166570A1
US20160166570A1 US14/892,287 US201414892287A US2016166570A1 US 20160166570 A1 US20160166570 A1 US 20160166570A1 US 201414892287 A US201414892287 A US 201414892287A US 2016166570 A1 US2016166570 A1 US 2016166570A1
Authority
US
United States
Prior art keywords
composition
group
menthol
icilin
linalool
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/892,287
Other languages
English (en)
Inventor
Susana Camacho
Stephanie Michlig Gonzalez
Johannes Le Coutre
Henry Markram
Maurizio Pezzoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Priority to US14/892,287 priority Critical patent/US20160166570A1/en
Publication of US20160166570A1 publication Critical patent/US20160166570A1/en
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PEZZOLI, Maurizio, CAMACHO, Susana, LE COUTRE, JOHANNES, MARKRAM, HENRY, MICHLIG GONZALEZ, STEPHANIE
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A23L1/30—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present disclosure generally relates to methods and compositions for prevention or treatment of non-inflammatory neuronal damage from brain trauma and strokes. More specifically, the present disclosure relates to compositions comprising at least one of Menthol, Linalool or Icilin and further relates to methods comprising administering such compositions.
  • glutamate accumulation leads to overstimulation of postsynaptic glutamate receptors with intracellular Ca 2+ overload and neuronal cell death.
  • glutamate antagonists are common neuroprotective treatments. These antagonists inhibit the binding of glutamate to NMDA receptors such that accumulation of Ca 2+ and therefore excitotoxicity can be avoided.
  • use of glutamate antagonists presents a huge obstacle because the treatment interferes with the normal action of glutamate under standard conditions.
  • a number of glutamate antagonists have been explored as options in central nervous system (CNS) disorders, but many are found to lack efficacy or have intolerable side effects.
  • the present inventors surprisingly and unexpectedly found that several active compounds from spices can depress neuronal activity in the neocortex and the amygdale. These compounds are Menthol and Linanool which are transient receptor potential M8 (TRPM8) channel agonists.
  • TRPM8 transient receptor potential M8
  • the present disclosure provides a method for treating non-inflammatory neuronal damage from a condition selected from the group consisting of brain trauma, a stroke and a combination thereof is provided.
  • the method comprises administering to an individual having such damage a composition comprising a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof.
  • the composition is selected from the group consisting of a medicament, a food product and a supplement to a food product.
  • a method for preventing non-inflammatory neuronal damage from a condition selected from the group consisting of brain trauma, a stroke and a combination thereof comprises administering to an individual having the condition a composition comprising a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof.
  • the composition is selected from the group consisting of a medicament, a food product and a supplement to a food product.
  • a method for preventing non-inflammatory neuronal apoptosis from a condition selected from the group consisting of brain trauma, a stroke and a combination thereof comprises administering to an individual a composition comprising a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof.
  • the composition is selected from the group consisting of a medicament, a food product and a supplement to a food product.
  • a method for preventing non-inflammatory neuronal necrosis comprises administering to an individual having the condition a composition comprising a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof.
  • the composition is selected from the group consisting of a medicament, a food product and a supplement to a food product.
  • compositions for neuroprotection against non-inflammatory neuronal damage from a condition selected from the group consisting of brain trauma, a stroke and a combination thereof comprises a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof.
  • the composition is a medicament.
  • the composition is a food product.
  • the food product can comprise a component selected from the group consisting of protein, carbohydrate, fat and combinations thereof.
  • the composition is a supplement to a food product.
  • the composition is a supplement to a food product.
  • An advantage of the present disclosure is to provide neuroprotection against non-inflammatory neuronal damage from brain trauma and strokes more effectively and/or more safely than glutamate antagonists.
  • Another advantage of the present disclosure is to prevent or treat non-inflammatory neuronal damage from brain trauma and strokes.
  • Still another advantage of the present disclosure is to prevent or treat non-inflammatory neuronal damage from brain trauma and strokes with compounds that can be easily and safely used in food products.
  • Yet another advantage of the present disclosure is to prevent or treat non-inflammatory neuronal damage from brain trauma and strokes by targeting the pre-synaptic phase of neuronal firing.
  • An additional advantage of the present disclosure is to prevent or treat non-inflammatory neuronal damage from brain trauma and strokes by targeting the pre-synaptic phase of neuronal firing while reducing the possibility of excitotoxicity.
  • Another advantage of the present disclosure is to prevent or treat non-inflammatory neuronal damage from brain trauma and strokes with naturally-occurring compounds that can be found in spices.
  • Still another advantage of the present disclosure is to prevent or treat non-inflammatory neuronal damage from brain trauma and strokes with tolerable side effects or no side effects.
  • FIG. 1 shows the chemical structures of compounds that can be used in embodiments of the composition according to the present disclosure.
  • FIG. 2 shows charts of whole cell, current clamp recordings in a Lateral Amygdala glutamatergic neuron (in a mouse brain slice) in the absence (control) and presence of the TRPM8 ligands Linalool, Icilin or Menthol.
  • FIG. 3 shows a chart of whole cell, current clamp recordings in a Lateral Amygdala glutamatergic neuron (in a mouse brain slice) with increasing concentration of gabazine (GABA A blocker) applied extracellularly during recordings of 5 min each (washout 10 min).
  • GABA A blocker gabazine
  • FIG. 4 shows a chart of whole cell, current clamp recordings in a Lateral Amygdala glutamatergic neuron (in a mouse brain slice) showing enhanced detail of a burst.
  • FIG. 5 shows a chart of whole cell, current clamp recordings in a Lateral Amygdala glutamatergic neuron (in a mouse brain slice) with increasing concentration of gabazine (GABA A blocker) applied extracellularly during recordings of 5 min each (washout 10 min.) while 10 minutes previous to and during the exposure of the different concentrations of gabazine, 250 ⁇ M menthol was also applied extracellularly.
  • GABA A blocker gabazine
  • neuronal survival refers to promotion of neuronal survival, promotion of neuronal repair, limiting neuronal oxidative stress, and/or limiting cell damage.
  • Cell damage is any impairment of function in a neuron, including cell death.
  • Cell death includes apoptosis and necrosis as non-limiting examples.
  • Non-inflammatory means unrelated to or not caused by neurogenic inflammation.
  • prevention includes reduction of risk and/or severity of non-inflammatory neuronal damage from brain trauma and strokes.
  • treatment includes both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder; and treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.
  • the term does not necessarily imply that a subject is treated until total recovery.
  • treatment also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition.
  • treatment,” “treat” and “to alleviate” are also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measure.
  • treatment,” “treat” and “to alleviate” are further intended to include the dietary management of a disease or condition or the dietary management for prophylaxis or prevention a disease or condition.
  • a treatment can be patient- or doctor-related.
  • a “therapeutically effective amount” is an amount that prevents a deficiency, treats a disease or medical condition in an individual or, more generally, reduces symptoms, manages progression of the diseases or provides a nutritional, physiological, or medical benefit to the individual.
  • Animal includes, but is not limited to, mammals, which includes but is not limited to, rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Where “animal,” “mammal” or a plural thereof is used, these terms also apply to any animal that is capable of the effect exhibited or intended to be exhibited by the context of the passage.
  • the term “patient” is understood to include an animal, especially a mammal, and more especially a human that is receiving or intended to receive treatment, as treatment is herein defined. While the terms “individual” and “patient” are often used herein to refer to a human, the present disclosure is not so limited. Accordingly, the terms “individual” and “patient” refer to any animal, mammal or human, having or at risk for a medical condition that can benefit from the treatment.
  • Food product and “food composition,” as used herein, are understood to include any number of optional additional ingredients, including conventional food additives, for example one or more proteins, carbohydrates, fats, acidulants, thickeners, buffers or agents for pH adjustment, chelating agents, colorants, emulsifiers, excipients, flavor agents, minerals, osmotic agents, a pharmaceutically acceptable carrier, preservatives, stabilizers, sugars, sweeteners, texturizers and/or vitamins.
  • the optional ingredients can be added in any suitable amount.
  • the present inventors surprisingly and unexpectedly found that several active compounds from spices can depress neuronal activity in neocortex and amygdale. These compounds are Menthol and Linanool which are transient receptor potential M8 (TRPM8) channel agonists.
  • TRPM8 transient receptor potential M8
  • the present inventors discovered the same effect with Icilin, a synthetic super-agonist of the TRPM8 ion channel, even though the structure of Icilin is not related with Menthol; nevertheless, Icilin produces an extreme sensation of cold both in humans and animals.
  • Menthol, Linanool and Icilin solves two main problems compared to neuroprotective glutamate antagonists: 1) Menthol, Linanool and Icilin target a presynaptic phase of APs, decreasing activity and diminishing glutamate release, which reduces drastically the possibility of reaching excitotoxicity levels; and 2) Menthol, Linanool and Icilin act stronger in the high stimulation context.
  • Menthol, Linanool and Icilin decrease neuronal activity, and target the pre-synaptic phase of the firing to reduce the possibilities of excitotoxicity one step earlier.
  • the composition provided by the present disclosure comprises a therapeutically effective amount of at least one of Menthol, Linalool or Icilin.
  • the Menthol, Linalool and/or Icilin can be therapeutically effective to provide neuroprotection against non-inflammatory neuronal damage from brain trauma and strokes.
  • Menthol, Linalool and/or Icilin can be therapeutically effective to treat or prevent non-inflammatory neuronal damage from brain trauma and strokes.
  • the composition comprising at least one of Menthol, Linalool or Icilin can be administered to an individual having brain trauma and/or a stroke to prevent or treat non-inflammatory neuronal damage from the brain trauma and/or stroke.
  • the neuroprotection, the treatment or the prevention can reduce or prevent neuronal cell damage, including cell death, such as neuronal apoptosis and/or neuronal necrosis, for example.
  • the composition comprising a therapeutically effective amount of at least one of Menthol, Linalool or Icilin is administered to a human.
  • Each of Menthol, Linalool and/or Icilin can be administered to the individual in a daily amount of 0.0015 mg/kg of body weight to 400 mg/kg of body weight, preferably 0.1 mg/kg of body weight to 300 mg/kg of body weight, more preferably 1.0 mg/kg of body weight to 200 mg/kg of body weight, and most preferably 10.0 mg/kg of body weight to 100 mg/kg of body weight.
  • each of Menthol, Linalool and/or Icilin can be administered to the individual in a daily amount of 0.0015 mg/kg of body weight to 0.01 mg/kg of body weight, 0.01 mg/kg of body weight to 0.1 mg/kg of body weight, 0.1 mg/kg of body weight to 1.0 mg/kg of body weight, 1.0 mg/kg of body weight to 10.0 mg/kg of body weight, 10.0 mg/kg of body weight to 100.0 mg/kg of body weight, 100.0 mg/kg of body weight to 200.0 mg/kg of body weight, 200.0 mg/kg of body weight to 300.0 mg/kg of body weight, or 300.0 mg/kg of body weight to 400.0 mg/kg of body weight.
  • the composition comprising at least one of Menthol, Linalool or Icilin may be a medicament, a food product or a supplement to a food product.
  • the supplement may be in the form of tablets, capsules, pastilles or a liquid, for example.
  • the supplement may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins or the like), adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (solvents), flowing agents, taste masking agents, weighting agents, jellifying agents and gel forming agents.
  • protective hydrocolloids such as gums, proteins, modified starches
  • binders film forming agents
  • encapsulating agents/materials, wall/shell materials matrix compounds
  • the supplement may also contain conventional pharmaceutical additives and adjuvants, excipients and diluents, including, but not limited to, water, gelatin of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
  • conventional pharmaceutical additives and adjuvants, excipients and diluents including, but not limited to, water, gelatin of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
  • the supplement can be added in a product acceptable to the consumer as an ingestible carrier or support.
  • Such carriers or supports are a pharmaceutical, a food composition, and a pet food composition.
  • Non-limiting examples for food and pet food compositions are milks, yogurts, curds, cheeses, fermented milks, milk-based fermented products, fermented cereal based products, milk-based powders, human milks, preterm formulas, infant formulas, oral supplements, and tube feedings.
  • the following non-limiting examples present scientific data developing and supporting the concept of treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes.
  • a mouse brain slice was used to study the damage from Menthol, Linalool and Icilin.
  • the amygdaloid complex is located within the medial temporal lobe in neocortex and amygdala.
  • the lateral and basolateral nuclei of the amygdaloid complex receive sensory information from cortical and thalamic structures, process the information, and then transmit the information, either directly or through the basal nucleus, to the central nucleus.
  • synaptic responses from the basolateral complex can be evoked electrically using electrodes, and the action potentials can be measured.
  • FIG. 2 shows recordings in the absence of Menthol, Linalool or Icilin (control) and recordings in the presence of Menthol, Linalool or Icilin.
  • a square pulse of 2.5s was applied at high depolarization of membrane potential (approximately ⁇ 30 mV).
  • the recordings show that, in the presence of the TRPM8 ligands at high depolarization levels, inactivation of the sodium fast channels happens sooner relative to control, avoiding further neuronal firing.
  • FIG. 3 shows recordings in increasing concentrations of gabazine, a GABA A blocker, applied extracellularly during recordings of 5 minutes each with 10 minute washout.
  • FIG. 4 depicts enhanced detail of one of the bursts and shows that serial action potentials can be observed in a single burst.
  • FIG. 5 shows recordings under the same conditions, namely increasing concentrations of gabazine applied extracellularly during recordings of 5 minutes each with 10 minute washout, except that in FIG. 5 , Menthol 250 ⁇ M was applied extracellularly at 10 minutes previous to and during the exposure of the different concentrations of gabazine.
  • neurons show a complete absence or a strongly decreased presence of spontaneous bursts (compare FIG. 5 to FIG. 3 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US14/892,287 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin Abandoned US20160166570A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/892,287 US20160166570A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827232P 2013-05-24 2013-05-24
PCT/EP2014/060637 WO2014187945A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin
US14/892,287 US20160166570A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/060637 A-371-Of-International WO2014187945A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/462,387 Division US10799502B2 (en) 2013-05-24 2017-03-17 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin

Publications (1)

Publication Number Publication Date
US20160166570A1 true US20160166570A1 (en) 2016-06-16

Family

ID=50819728

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/892,287 Abandoned US20160166570A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin
US15/462,387 Active US10799502B2 (en) 2013-05-24 2017-03-17 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/462,387 Active US10799502B2 (en) 2013-05-24 2017-03-17 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin

Country Status (10)

Country Link
US (2) US20160166570A1 (ja)
EP (1) EP3003292B1 (ja)
JP (2) JP2016520588A (ja)
CN (1) CN105228601A (ja)
AU (2) AU2014270341A1 (ja)
BR (1) BR112015026484A2 (ja)
CA (1) CA2908365C (ja)
ES (1) ES2721922T3 (ja)
TR (1) TR201906539T4 (ja)
WO (1) WO2014187945A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160166570A1 (en) * 2013-05-24 2016-06-16 Nestec S.A. Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin
CN116018134A (zh) * 2020-03-24 2023-04-25 洪明奇 薄荷醇用于制备治疗神经退化症及中风的外用组合物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371276A1 (en) * 2011-12-19 2014-12-18 Alessio Moriconi Trpm8 antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164828A0 (en) * 2002-04-25 2005-12-18 Brainsgate Ltd Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
JP4742204B2 (ja) * 2005-01-21 2011-08-10 財団法人ヒューマンサイエンス振興財団 脂肪細胞分化制御剤
JP2007291069A (ja) * 2006-03-31 2007-11-08 Daiichi Sankyo Healthcare Co Ltd 抗酸化剤および／または消炎鎮痛剤組成物
GB0615136D0 (en) * 2006-07-29 2006-09-06 Univ Edinburgh Induction of analgesia in neuropathic pain
KR20090085237A (ko) * 2008-02-04 2009-08-07 김병문 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물
EP3485881B1 (en) * 2009-07-10 2024-03-13 President and Fellows of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물
CN102512634A (zh) * 2011-12-26 2012-06-27 神威药业（张家口）有限公司 复方麝香软胶囊及其制备方法
US20150320700A1 (en) * 2012-05-07 2015-11-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Reserc Organizatio Geranium oil and constituents thereof for treatment of neurodegenerative diseases
US20160166570A1 (en) * 2013-05-24 2016-06-16 Nestec S.A. Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371276A1 (en) * 2011-12-19 2014-12-18 Alessio Moriconi Trpm8 antagonists

Also Published As

Publication number Publication date
CN105228601A (zh) 2016-01-06
CA2908365A1 (en) 2014-11-27
JP2020011985A (ja) 2020-01-23
AU2019222781A1 (en) 2019-09-12
US10799502B2 (en) 2020-10-13
ES2721922T3 (es) 2019-08-06
CA2908365C (en) 2023-02-28
EP3003292A1 (en) 2016-04-13
JP2016520588A (ja) 2016-07-14
EP3003292B1 (en) 2019-03-20
AU2019222781B2 (en) 2021-05-13
US20170189403A1 (en) 2017-07-06
WO2014187945A1 (en) 2014-11-27
AU2014270341A1 (en) 2015-10-08
BR112015026484A2 (pt) 2017-07-25
TR201906539T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
US20160108004A1 (en) Treatment or prevention of neurodegenerative disorders using menthol, linalool and/or icilin
AU2019222781B2 (en) Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin
AU2020202020A1 (en) Methods and compositions for increasing energy expenditure using cinnamaldehyde
US11241433B2 (en) Treatment or prevention of autism disorders using menthol, linalool and/or icilin
US20160108005A1 (en) Treatment or prevention of depression using menthol and/or icilin

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAMACHO, SUSANA;MICHLIG GONZALEZ, STEPHANIE;LE COUTRE, JOHANNES;AND OTHERS;SIGNING DATES FROM 20140902 TO 20141002;REEL/FRAME:042208/0231

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION